Key Financials –
FY2021 Earnings

FY2021 Revenue $275.9m +323% YoY
FY2021 Adjusted EBITDA
$40.9m
Forecast 2025 Revenue +$600m
Laboratory and rapid
at-home tests 22 million+

Prenetics Delivers Exceptional FY2021 Results as Company Completes Business Combination with Artisan Acquisition Corp. to list on Nasdaq Stock Exchange

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

18 May 22
Prenetics Rings the Opening Bell and Debuts on Nasdaq
Prenetics becomes the first Hong Kong unicorn to list on Nasdaq and its shares began trading on May 18 under ticker “PRE” At Least US$260M of Proceeds from the Business Combination, Cash and Trade Receivables to Support Prenetics Growth Proceeds will allow Prenetics to continue its significant

Recent Events

Featured Reports